Teknova to Report Third Quarter 2021 Financial Results on November 10, 2021
04 November 2021 - 7:05AM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider
of critical reagents for the development and production of
biopharmaceutical products including drug therapies, novel
vaccines, and molecular diagnostics, today announced that it will
report its financial results for the third quarter of 2021 on
Wednesday, November 10, 2021, following the close of market.
Teknova will host a webcast and conference call
on Wednesday, November 10, beginning at 4:30 p.m. ET. Participants
may access the live webcast on the Investor Relations section of
the Teknova website and at this link:
https://edge.media-server.com/mmc/p/vjhnni3v. The conference call
can be accessed by dialing 877-312-1451 for domestic callers and
470-495-9521 for international callers. The conference ID number is
5889934. A replay will be available for 30 days on the Investor
Relations section of the Teknova website,
https://www.teknova.com.
About Teknova
Teknova is expediting clinical breakthroughs in
the life sciences by providing custom products and reagents for
bioprocessing, bioproduction, and molecular diagnostics. With a
focus on agility and customization, Teknova delivers research-grade
and GMP products including cell culture media and supplements,
protein and nucleic acid purification buffers, and molecular
biology reagents for a multitude of established and emerging
applications, including cell and gene therapy, mRNA therapeutics,
genomics, and synthetic biology. Teknova's proprietary processes
enable the manufacture and delivery of high quality, custom,
made-to-order products on short turnaround times and at scale
across all stages of development, including commercialization.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements relating to our long-term growth strategy,
demand for our products, expansion of our production capacity and
commercial and R&D capabilities. The words, without limitation,
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. These forward-looking statements are based on management’s
current expectations and beliefs and are subject to uncertainties
and factors, all of which are difficult to predict and many of
which are beyond our control and could cause actual results to
differ materially and adversely from those described in the
forward-looking statements. These risks include, but are not
limited to, those related to our cash flows and revenue growth
rate; our supply chain, sourcing, manufacturing and warehousing;
inventory management; risks related to global economic and
marketplace uncertainties related to the impact of the COVID-19
pandemic; reliance on a limited number of customers for a high
percentage of our revenue; acquisitions of other companies and
other factors discussed in the “Risk Factors” section of our most
recent periodic reports filed with the Securities and Exchange
Commission (“SEC”), including in our final prospectus filed with
the SEC pursuant to Rule 424(b) under the Securities Act of 1933,
as amended, on June 25, 2021, all of which you may obtain for
free on the SEC’s website at www.sec.gov. Although we believe that
the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-216-1830
Sara Michelmore
MacDougall Advisors
smichelmore@macbiocom.com
+1 781-235-3060
Media Contact
Matthew Corcoran
MacDougall Advisors
mcorcoran@macbiocom.com
+1 617-866-7350
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Apr 2023 to Apr 2024